Abstract:Abstract Background Glioma is one of the main causes of cancer-related mortality worldwide and is associated with high heterogeneity. However, the key players determining the fate of glioma remain obscure. In the present study, we shed light on tumor metabolism and aimed to investigate the role of tryptophan hydroxylase 1 (TPH-1) in the advancement of glioma. Method Herein, the levels of TPH-1 expression in glioma tissues were evaluated using The Cancer Genome Atlas (TCGA) database. Further, the proliferative characteristics and migration ability of TPH-1 overexpressing LN229/T98G cells were evaluated. Additionally, we performed a cytotoxicity analysis using temozolomide (TMZ) in these cells. We also examined the tumor growth and survival time in a mouse model of glioma treated with chemotherapeutic agents and a TPH-1 inhibitor. Results The results of both clinical and experimental data showed that excess TPH-1 expression resulted in sustained glioma progression and a dismal overall survival in these patients. Mechanistically, TPH-1 increased the production of serotonin in glioma cells. The elevated serotonin levels then augmented the NF-κB signaling pathway through the upregulation of the L1-cell adhesion molecule (L1CAM), thereby contributing to cellular proliferation, invasive migration, and drug resistance. In vivo experiments demonstrated potent antitumor effects, which benefited further from the synergistic combination of TMZ and LX-1031. Conclusion Taken together, these data suggested that TPH-1 facilitated cellular proliferation, migration, and chemoresistance in glioma through the serotonin/L1CAM/NF-κB pathway. By demonstrating the link of amino acid metabolic enzymes with tumor development, our findings may provide a potentially viable target for therapeutic manipulation aimed at eradicating glioma.

TFCP2, a binding protein of ATF3, promotes the progression of glioma by activating the synthesis of serine

PSMC2/E2F1 Axis Promotes the Development and Progression of Glioma

TCF3 Induces DNMT1 Expression to Regulate Wnt Signaling Pathway in Glioma

ATF3 promotes the serine synthesis pathway and tumor growth under dietary serine restriction

Tryptophan hydroxylase 1 drives glioma progression by modulating the serotonin/L1CAM/NF-κB signaling pathway

CDC42EP3 promotes glioma progression via regulation of CCND1

RNA-binding Protein PCBP2 Modulates Glioma Growth by Regulating FHL3.

NT5DC2 Promotes Tumorigenicity of Glioma Stem-like Cells by Upregulating Fyn.

Inhibition of translocator protein 18 kDa suppressed the progression of glioma via the ELAV-like RNA-binding protein 1/MAPK-activated protein kinase 3 axis

GCN5 Potentiates Glioma Proliferation and Invasion via STAT3 and AKT Signaling Pathways

GSK-3 beta regulates tumor growth and angiogenesis in human glioma cells

TFCP2 Activates Beta-Catenin/tcf Signaling in the Progression of Pancreatic Cancer.

TIFA enhances glycolysis through E2F1 and promotes the progression of glioma

Chromatin Licensing and DNA Replication Factor 1 (CDT1) Is a Potential Prognostic Biomarker Involved in the Malignant Biological Behavior of Glioma

TGF-β Signaling Promotes Glioma Progression Through Stabilizing Sox9

PTRF/cavin-1 remodels phospholipid metabolism to promote tumor proliferation and suppress immune responses in glioblastoma by stabilizing cPLA2

GTF2E2 Downregulated by Mir-340-5p Inhibits the Malignant Progression of Glioblastoma

Molecular Targeting of TRF2 Suppresses the Growth and Tumorigenesis of Glioblastoma Stem Cells.

Downregulation of HTATIP2 expression is associated with promoter methylation and poor prognosis in glioma.

Shuttling SLC2A4RG is Regulated by 14-3-3θ to Modulate Cell Survival Via Caspase-3 and Caspase-6 in Human Glioma

ITPKA phosphorylates PYCR1 and promotes the progression of glioma